Clinical Trial Update: 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for 506U78 in patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma (NCI-sponsored). The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma

Drugs mentioned

• 506U78

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, Lymphoma | Phase 2 | Status: COMPLETED